InsidersTradesSigma
Total declarations
Companies
▲ Purchases (0 ops.)
▼ Sales (2 ops.)
Insider track record
ExecutiveDisclosed buys
0
Disclosed sells
2
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
No signal scores available.
Discover the complete record of transactions filed by Agarwal Sunil, Directeur du Développement et Directeur Marketing. Officer active across 3 companies, notably Sana Biotechnology, Inc.. In total, 6 disclosures have been recorded. Breakdown: 0 buy · 2 sells. Total volume traded: €1.3m. History available since 15 September 2021. The latest transaction was disclosed on 25 June 2025 (Attribution). Regulator: SEC (Form 4). All data is free.
Companies and markets linked to Agarwal Sunil
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations6 total
16,025 shares0Common StockSEC:0001655759-25-000126:0
5,899 shares0Common StockSEC:0001655759-24-000084:0
8,242 shares0Common StockSEC:0001655759-23-000059:0
58,373 shares@ US$26.0695100.0% of flowCommon StockSEC:0001562180-21-005999:0
456 sharesCommon StockSEC:0001562180-16-001371:0
585 sharesCommon StockSEC:0001562180-16-001371:1
6 of 6 declarations
About Agarwal Sunil
AGARWAL SUNIL is Director of Development and Marketing Director. He has 6 filings in total, and across the sampled recent filings, the reported sell volume is 1287441 EUR, covering the period from 2016-01-21 to 2025-06-30. The companies mentioned are Arvinas, INC., Ultragenyx Pharmaceutical Inc. and Sana Biotechnology, Inc., and the modal transaction nature is Attribution.
